上海凯茂生物医药

Shanghai Kaimao Biopharmaceutical is a specialized biotechnology company focused on the research, development, and manufacturing of recombinant protein therapeutics. As a key subsidiary of North China Pharmaceutical Group (NCPC), the company operates a high-tech industrialization base in Shanghai's Zhangjiang Hi-Tech Park. Its flagship products include recombinant human erythropoietin (rhEPO) for anemia and recombinant human prourokinase (rhpro-UK) for the treatment of acute myocardial infarction. The company maintains advanced GMP-certified facilities for large-scale biologics production and continues to expand its pipeline in the cardiovascular and hematology therapeutic areas. Shanghai Kaimao is recognized as a National High-Tech Enterprise and plays a central role in the biologics strategy of its parent organization.